ASO Author Reflections: Precision Surgery in Patients with Colorectal Peritoneal Metastases: Bridging the Gap Between Biological Complexity and Therapeutic Options

Affiliations

¹ Peritoneal Malignancy Institute, Basingstoke North Hampshire Hospital Foundation Trust, Basingstoke, UK. niccolo.allievi@gmail.com.
² Peritoneal Malignancy Institute, Basingstoke North Hampshire Hospital Foundation Trust, Basingstoke, UK.

Niccolo Allievi et al. Ann Surg Oncol. 2024 Dec.

. 2024 Dec;31(13):8596-8597.

doi: 10.1245/s10434-024-16082-2. Epub 2024 Aug 20.

¹ Peritoneal Malignancy Institute, Basingstoke North Hampshire Hospital Foundation Trust, Basingstoke, UK. niccolo.allievi@gmail.com.
² Peritoneal Malignancy Institute, Basingstoke North Hampshire Hospital Foundation Trust, Basingstoke, UK.

No abstract available

References

1. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32. - DOI - PubMed
1. Allievi N, Sidhom M, Samuel VM, et al. Survival analysis and recurrence patterns in 555 patients with colorectal peritoneal metastases treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15942-1 . - DOI - PubMed
1. Lenos KJ, Bach S, Ferreira Moreno L, et al. Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nat Commun. 2022;13:4443. - DOI - PubMed - PMC
1. Betge J, Rindtorff N, Sauer J, et al. The drug-induced phenotypic landscape of colorectal cancer organoids. Nat Commun. 2022;13:3135. - DOI - PubMed - PMC